VIVUS, Inc. (NASDAQ:VVUS)
CAPS Rating:
A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.
RSS Headlines
Fool UK
Recs
Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.